convalescent plasma-Universitaire Ziekenhuizen KU Leuven-COVID-19

Convalescent plasma-Universitaire Ziekenhuizen KU Leuven-COVID-19 refers to the specific investigational passive immunotherapy used in the DAWn-PLASMA (Donated Antibodies Working against nCoV) clinical trial. Coordinated by University Hospitals Leuven (UZ Leuven) in Belgium, this therapy consists of plasma units collected from donors who have recovered from COVID-19, specifically those with high neutralizing antibody titers (NT50 ≥1/320). The mechanism of action involves the transfer of these antibodies to hospitalized patients to provide immediate passive immunity by neutralizing the SARS-CoV-2 virus and preventing further cellular entry. Despite the theoretical benefit of borrowed immunity, the phase II DAWn-PLASMA trial involving 483 patients across 22 Belgian centers concluded that the transfusion of high-titer convalescent plasma did not significantly improve clinical outcomes or reduce mortality in hospitalized COVID-19 patients.

Other names

COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaDonated Antibodies Working against nCoV